1. Home
  2. Directory
  3. Washington
  4. Sunnyside
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1124229869

DR. MAHAKIT INKLAB MD
Prescription History 1124229869
Internal Medicine - Hematology & Oncology in Sunnyside, WA

NPI Status: Active since May 30, 2007

Contact Information

1013 E. EDISON AVE
SUNNYSIDE, WA
ZIP 98944
Phone: (509) 837-1587

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. MAHAKIT INKLAB MD, an active Hematology & Oncology specialist practicing in Sunnyside, WA. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 64 documented patient claims. Among these therapy options, the most frequently utilized medication is Anastrozole, which accounts for 27 claims alone.

Medication Index

A
H
L
X
No matching medications currently found on file.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 27
30-Day Fills 55.0
Days Supply 1,650
WA State Average Benchmarks
Peer Average Claims65.0
Peer Average 30-Day Fills153.2
Peer Average Days Supply4,576
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 58.5% less volume than the regional standard for practitioners inside WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $879.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$32.56

State Avg Cost Per Claim

$26.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 15.1
Days Supply 433
WA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills61.0
Peer Average Days Supply1,806
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.6% less volume than the regional standard for practitioners inside WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $398.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$36.23

State Avg Cost Per Claim

$39.43

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Letrozole

Generic Formulation: LetrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 40.0
Days Supply 1,200
WA State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills116.7
Peer Average Days Supply3,483
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.5% less volume than the regional standard for practitioners inside WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $343.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.55

State Avg Cost Per Claim

$27.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 25.0
Days Supply 743
WA State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills71.1
Peer Average Days Supply2,054
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.4% less volume than the regional standard for practitioners inside WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $14,978.34 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,248.20

State Avg Cost Per Claim

$955.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. MAHAKIT INKLAB MD provides transparency into local medical care patterns within Sunnyside, WA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.